Core Insights - XOMA Royalty Corporation has acquired future royalty and milestone interests in mezagitamab from BioInvent for a total of USD $30 million, with an initial payment of USD $20 million at closing [1][2] - The acquisition enhances XOMA Royalty's late-stage royalty portfolio and provides BioInvent with non-dilutive capital to advance its clinical pipeline [2] - XOMA Royalty will be entitled to additional milestones of up to USD $16.25 million and mid-single digit royalties on future commercial sales of mezagitamab [3] Company Overview - XOMA Royalty Corporation is a biotechnology royalty aggregator that helps biotech companies by acquiring potential future economics associated with therapeutic candidates [5] - BioInvent International AB focuses on discovering and developing novel immune-modulatory antibodies for cancer therapy, currently having five drug candidates in clinical trials [6] Transaction Details - The economic interest in mezagitamab originated from a 2003 cross-licensing agreement between XOMA Royalty and BioInvent [2] - An additional payment of USD $10 million will be made upon mezagitamab achieving a specific regulatory milestone related to FDA marketing approval for IgA nephropathy [2] Clinical Development - Takeda, the developer of mezagitamab, has initiated a Phase 3 clinical trial for the treatment of immune thrombocytopenia (ITP) [4] - Mezagitamab is a fully human IgG1 monoclonal antibody targeting CD38, which has the potential to be a best-in-class anti-CD38 mAb [4]

Core Insights - Western Digital Corporation (WDC) is advancing storage innovation with a focus on AI/ML, software-defined storage, and disaggregated storage solutions tailored for hyperscale cloud service providers and enterprises [1][2] - The company has launched significant enhancements to its Open Composable Compatibility Lab (OCCL), including OCCL 2.0 and new storage products, to meet the growing demand for scalable and efficient storage systems [2][4] Group 1: Product Innovations - The introduction of the OpenFlex Data24 4100 EBOF and Ultrastar Data102 ORv3 JBOD aims to improve efficiency and manageability in cloud environments [3] - OCCL 2.0 provides comprehensive solutions architecture guidance, best practice frameworks, and benchmarking tools to enhance storage efficiency and interoperability [4] - The lab collaborates with various ecosystem partners to promote open, fabric-attached storage and SDS solutions, moving away from proprietary models [5] Group 2: Market Trends and Demand - The rise of generative AI is expected to drive a refresh cycle in client and consumer devices, increasing storage demand across both HDD and Flash technologies [6] - High-bandwidth memory (HBM) is becoming essential for AI servers, while NAND flash remains critical for powering SSDs, with eSSD sales growing due to their advantages over HDDs [7] - The increasing adoption of AI is reshaping the storage market, leading to heightened demand for efficient storage solutions [7]

Core Insights - XOMA Royalty Corporation reported a strong first quarter for 2025, with total income and revenues of $15.9 million, a significant increase from $1.5 million in the same period in 2024, driven by various milestone payments and royalties [7][21]. - The company received $18.0 million in cash receipts during the first quarter, including $13.4 million from royalties and commercial payments, and $4.6 million from milestones and fees [15][7]. - XOMA Royalty is focused on prudent cash deployment, strict expense control, and opportunistic share repurchases, indicating a commitment to generating shareholder value [2][6]. Pipeline Advancements - The Marketing Authorization Application (MAA) for tovorafenib by Day One Biopharmaceuticals and Ipsen was accepted for review by the European Marketing Authority (EMA) [1]. - Takeda initiated a Phase 3 trial for mezagitamab, targeting chronic primary immune thrombocytopenia [1]. Business Development - XOMA Royalty acquired a royalty interest in Castle Creek Biosciences' D-Fi (FCX-007), a Phase 3 asset for dystrophic epidermolysis bullosa, contributing $5 million to a $75 million syndicated royalty financing transaction [3][1]. - The company successfully sold all unpartnered Kinnate assets, with a portion of any upfront payments to be distributed to Kinnate CVR holders [1][3]. Financial Performance - The company recorded a net income of $2.4 million for the first quarter of 2025, compared to a net loss of $8.6 million in the first quarter of 2024 [14][22]. - Research and Development (R&D) expenses increased to $1.3 million in Q1 2025 from $33,000 in Q1 2024, primarily due to licensing fees and clinical trial costs [9][21]. - General and Administrative (G&A) expenses decreased to $8.1 million in Q1 2025 from $8.5 million in Q1 2024, mainly due to lower stock compensation costs [10][11]. Anticipated Events - Key upcoming events include the EMA's decision on the MAA for tovorafenib and the completion of enrollment in the sunRIZE Phase 3 clinical trial for ersodetug, with topline data expected in December 2025 [6][1].

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Credit: CC0 Public Domain When it comes to Facebook, news matters—not the fake stuff but the real kind generated by working journalists. That's the takeaway of a University of Michigan study, which sought to examine how news content affects news aggregators and the presence of it affects user engagement and content generation ...

Core Insights - Ligand Pharmaceuticals reported a strong first quarter performance with total revenues of $45.3 million, a 46% increase from $31.0 million in the same period of 2024, driven by a 44% growth in royalty revenue [4][5] - The company reaffirmed its 2025 financial guidance, expecting total revenues between $180 million and $200 million, with adjusted earnings per diluted share projected to be between $6.00 and $6.25 [8][7] - Ligand's CEO highlighted the strength of the commercial royalty portfolio and the strategic transaction with Channel Therapeutics to accelerate the launch of ZELSUVMI, which is expected to create significant value for shareholders [3][9] Financial Performance - Total revenues for Q1 2025 were $45.3 million, with royalties contributing $27.5 million and Captisol sales at $13.5 million [4][5] - Research and development expenses surged to $50.1 million, primarily due to a one-time charge of $44.3 million related to a royalty financing agreement with Castle Creek Biosciences [4][5] - The GAAP net loss for Q1 2025 was $42.5 million, or $2.21 per share, compared to a net income of $86.1 million, or $4.75 per diluted share, in Q1 2024 [5][29] Strategic Transactions - Ligand announced a merger agreement with Channel Therapeutics, which will be supported by $50 million in capital from strategic investors [9][10] - The combined entity will focus on the commercialization of ZELSUVMI, the first FDA-approved prescription therapy for molluscum contagiosum infections [11][9] - Ligand's investment of $18 million in the combined company reflects its commitment to the growth of Pelthos Therapeutics [10][9] Portfolio Updates - Verona reported Ohtuvayre net sales of $71.3 million for Q1 2025, a 95% increase compared to the previous quarter [13] - Travere Therapeutics received European Commission approval for Filspari, enhancing its market position [14] - UroGen and Merck also reported significant advancements in their respective product pipelines, indicating a robust biopharmaceutical landscape [15][17] Cash Position - As of March 31, 2025, Ligand had cash, cash equivalents, and short-term investments totaling $208.9 million, including $24.2 million in Viking Therapeutics common stock [6][32]

Sabre (SABR) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Brian Evans - SVP, Investor Relation & TreasurerKurt Ekert - President & Chief Executive OfficerMike Randolfi - Chief Financial OfficerJed Kelly - Managing Director - Equity ResearchJames Goodall - Director & Head - Transport & Leisure Conference Call Participants Victor Cheng - AnalystJoshua Baer - AnalystJeff Harlib - AnalystNone - AnalystAlex Irving - Analyst Operator Good morning, and welcome to the Sabre First Quarter twen ...

fuboTV (FUBO) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Ameet Padte - SVP of FP&A, Corporate Development & Investor RelationsDavid Gandler - Co-Founder, CEO & DirectorJohn Janedis - CFOClark Lampen - Managing DirectorAlicia Reese - SVP - Equity Research Conference Call Participants David Joyce - Senior Equity Analyst - Media SectorLaura Martin - Managing Director, Senior Internet & Media Analyst Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your c ...

fuboTV (FUBO) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Ameet Padte - SVP of FP&A, Corporate Development & Investor RelationsDavid Gandler - Co-Founder, CEO & DirectorJohn Janedis - CFOClark Lampen - Managing DirectorAlicia Reese - SVP - Equity Research Conference Call Participants David Joyce - Senior Equity Analyst - Media SectorLaura Martin - Managing Director, Senior Internet & Media Analyst Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your c ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported total revenue of $407.9 million in North America, reflecting a year-over-year increase of 3.5% [6][11] - Net income from continuing operations was $188 million, translating to $0.55 per diluted share, compared to a net loss of $56.3 million and a loss per share of $0.19 in the prior year [12] - Adjusted EBITDA improved by $37 million year-over-year, reaching negative $1.4 million, indicating effective cost control and operational efficiency [12][13] Business Line Data and Key Metrics Changes - The North American streaming business had 1,470,000 paid subscribers, down 2.7% year-over-year but exceeding the Q1 guidance of 1,460,000 [6][11] - Advertising revenue for the quarter was $22.5 million, down 17% year-over-year, primarily due to the discontinuation of Warner Bros. Discovery and TelevisaUnivision Networks [11][12] Market Data and Key Metrics Changes - The company anticipates a decline in subscribers for Q2 2025, projecting 1,225,000 to 1,255,000 subscribers, which represents a 14% year-over-year decline at the midpoint [13][14] - For the Rest of World segment, Q2 guidance projects subscribers of 325,000 to 335,000, down 17% year-over-year, with revenue expected to decline by 15% at the midpoint [14] Company Strategy and Development Direction - The company is focused on achieving profitability in 2025 while continuing to enhance its content offerings and flexible packaging options [7][10] - The pending business combination with Hulu plus Live TV is seen as a strategic move to increase competition and consumer choice in the pay TV space [7][14] - The company is committed to negotiating content licensing agreements at fair rates and terms to support its skinny bundle offerings [10][22] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to navigate economic uncertainties and the evolving streaming landscape [6][7] - The company noted that while subscriber growth is expected to be modest, reactivations were better than anticipated in April, indicating resilience in customer demand [26] - Management emphasized the importance of profitability over growth, particularly in international markets, and is preparing for future expansion [31][33] Other Important Information - The company has made significant investments in technology and strategic content changes, resulting in improved profitability and cash flow [14] - The company is focused on interactive and gamified advertising formats, which have shown a year-over-year increase in traction [40][41] Q&A Session Summary Question: Update on content discussions with Televisa Univision - Management indicated no new updates but remains open to discussions under acceptable terms, while also noting a reduction in the price of the Latino package [18][19] Question: Impact of macroeconomic conditions on subscriber growth and advertising - Management reported that churn rates are in line with expectations and that April showed better-than-expected reactivations, with advertising growth improving [24][26] Question: Concerns about the Rest of World segment and GenAI integration - Management reiterated the focus on profitability for the Rest of World segment and highlighted the importance of technology and marketing investments for future growth [31][33] Question: Explanation for the decline in advertising revenue - Management clarified that the loss of ad-insertable hours from certain networks directly impacted ad revenue, but normalized figures would show slight year-over-year growth [35][36] Question: Performance of gamified ads and advertiser interest - Management reported a 30% year-over-year increase in interactive ads and noted strong interest from advertisers despite tightening budgets [40][41]

Company Overview - WM Technology, Inc. operates an online marketplace and data aggregator specifically for the cannabis industry, known as Weedmaps, which facilitates education and compliant transactions for users and vendors [1]. Market Position - The platform allows users to learn about cannabis products while enabling vendors to sell their products in a compliant manner, indicating a strong positioning within the cannabis market [1].